Advertisement
Screener

VAXCYTE, INC. (PCVX) Price / Book

2.8 / 5 stars · 68/120 Roast Me

Vaxcyte, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

  • Vaxcyte, Inc. price/book ratio for the quarter ending 2026-06-30 was 3.05, a 121.96% increase year-over-year.
  • Vaxcyte, Inc. price/book ratio for the quarter ending 2026-03-31 was 2.8, a 83.85% increase year-over-year.
  • Vaxcyte, Inc. price/book ratio for the quarter ending 2025-12-31 was 2.25, a 27.21% decline year-over-year.
  • Vaxcyte, Inc. price/book ratio for the quarter ending 2025-09-30 was 1.62, a 61.07% decline year-over-year.
  • Vaxcyte, Inc. price/book ratio for fiscal 2026 was 3.05.
  • Vaxcyte, Inc. price/book ratio for fiscal 2025 was 2.25, a 27.21% decline from fiscal 2024.
  • Vaxcyte, Inc. price/book ratio for fiscal 2024 was 3.09, a 35.94% decline from fiscal 2023.
  • Vaxcyte, Inc. price/book ratio for fiscal 2023 was 4.83, a 20.82% increase from fiscal 2022.
Available history
2020-06-30 to 2026-06-30
Data captured

Historical Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-303.05$8.42B$2.76B
2026-03-312.8$8.38B$3B
2025-12-312.25$6.05B$2.69B
2025-09-301.62$4.68B$2.89B
2025-06-301.38$4.22B$3.07B
2025-03-311.52$4.87B$3.2B
2024-12-313.09$10.22B$3.31B
2024-09-304.16$14.22B$3.42B
2024-06-304.2$8.35B$1.99B
2024-03-313.74$7.43B$1.98B
2023-12-314.83$5.99B$1.24B
2023-09-303.46$4.85B$1.4B
2023-06-303.27$4.68B$1.43B
2023-03-313.2$3.02B$944.77M
2022-12-314$3.81B$953.61M
2022-09-304.05$1.45B$359.31M
2022-06-303.48$1.28B$366.5M
2022-03-313.79$1.36B$359.54M
2021-12-314.44$1.26B$284.02M
2021-09-304.36$1.33B$305.96M
2021-06-303.69$1.17B$317.03M
2021-03-313.1$1.01B$326.94M
2020-12-313.92$1.36B$345.84M
2020-09-306.91$2.52B$364.08M
2020-06-304.2$1.61B$383.21M

Annual Price/Book Ratio

DatePrice/Book RatioMarket capitalizationShareholder equity
2026-06-303.05$8.42B$2.76B
2025-12-312.25$6.05B$2.69B
2024-12-313.09$10.22B$3.31B
2023-12-314.83$5.99B$1.24B
2022-12-314$3.81B$953.61M
2021-12-314.44$1.26B$284.02M
2020-12-313.92$1.36B$345.84M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68